Ozturk, Sait
Mathur, Deepti
Zhou, Royce W.
Mulholland, David
Parsons, Ramon http://orcid.org/0000-0002-6656-3514
Funding for this research was provided by:
Prostate Cancer Foundation (16CHAL14)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA220491, CA196521)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 15 April 2020
Revised: 8 June 2020
Accepted: 30 June 2020
First Online: 13 July 2020
Compliance with ethical standards
:
: RP is a shareholder of Therapten, Inc., a company focused on using an isoform of PTEN protein as a treatment for disease. The authors declare that they have no conflict of interest.